THE MACROLIDE-LINCOSAMIDE-STREPTOGRAMIN-B RESISTANCE PHENOTYPES CHARACTERIZED BY USING A SPECIFICALLY DELETED, ANTIBIOTIC-SENSITIVE STRAIN OF STREPTOMYCES-LIVIDANS
Jl. Pernodet et al., THE MACROLIDE-LINCOSAMIDE-STREPTOGRAMIN-B RESISTANCE PHENOTYPES CHARACTERIZED BY USING A SPECIFICALLY DELETED, ANTIBIOTIC-SENSITIVE STRAIN OF STREPTOMYCES-LIVIDANS, Antimicrobial agents and chemotherapy, 40(3), 1996, pp. 581-585
Genes conferring resistance to macrolide, lincosamide, and streptogram
in B (MLS) antibiotics via ribosomal modification are widespread in ba
cteria, including clinical isolates and MLS-producing actinomycetes, S
uch erm-type genes encode enzymes that mono- or dimethylate residue A-
2058 of 23S rRNA. The different phenotypes resulting from monomethylat
ion (MLS-I phenotype, conferred by erm type I genes) or dimethylation
(MLS-II phenotype due to erm type II genes) have been characterized by
introducing tlrD or ermE, respectively, into an MLS-sensitive derivat
ive of Streptomyces lividans TK21, This strain (designated OS456) was
generated by specific replacement of the endogenous resistance genes I
rm and mgt. The MLS-I phenotype is characterized by high-level resista
nce to lincomycin with only marginal resistance to macrolides such as
chalcomycin or tylosin, whereas the MLS-II phenotype involves high-lev
el resistance to all MLS drugs. Mono- and dimethylated ribosomes were
introduced into a cell-free protein-synthesizing system prepared from
S. lividans and compared,vith unmodified particles in their response t
o antibiotics. There was no simple correlation between the relative po
tencies of MLS drugs at the level of the target site (i.e., the riboso
me) and their antibacterial activities expressed as MICs.